Evidence map›Paper›PMID 39589151›Full record

ArticleJournal of virology2024

Influenza virus infection and aerosol shedding kinetics in a controlled human infection model.

Nishit Shetty, Meredith J Shephard, Nicole C Rockey, Hollie Macenczak, Jessica Traenkner, Shamika Danzy, Nahara Vargas-Maldonado, Peter J Arts, Valerie Le Sage, Evan J Anderson and 11 more

Erratum issued 2 registry-linked trialsAbstract readClinical Trial, Phase I
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05332899 phase1recruitingnot on this map

Influenza Human Challenge Model

TypeinterventionalSponsorEmory UniversityRan2022 to 2027Enrolled80ConditionsInfluenzaArmsInfluenza Virus Type A H3N2 Challenge
NCT07063849 phase1active not recruitingnot on this mapstarted 2025, after this paper: background citation

A Pilot Study of the Effects of Pre-Existing Immunity on Influenza A/Texas/71/2017 (H3N2) Virus Shedding After Human Challenge in Healthy Participants

TypeinterventionalSponsorDaniel Hoft, MD, PhDRan2025 to 2026Enrolled12ConditionsInfluenzaArmsA/Texas
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Prophylactic Efficacy of CD388, a Novel Drug-Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Trial
  3. Article
  4. Article
  5. Detection of SARS-CoV-2 RNA on air purifier filters in university spaces without symptomatic or confirmed cases.Aerosol science and technology : the journal of the American Association for Aerosol Research · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Nishit Shetty *Department of Civil and Environmental Engineering, Virginia Tech, Blacksburg, Virginia, USA.ORCID 0000-0002-0488-7716
Meredith J Shephard *Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0003-4035-6653
Nicole C RockeyDepartment of Civil and Environmental Engineering, Duke University, Durham, North Carolina, USA.
Hollie MacenczakHope Clinic, Emory University, Decatur, Georgia, USA.
Jessica TraenknerHope Clinic, Emory University, Decatur, Georgia, USA.
Shamika DanzyDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.
Nahara Vargas-MaldonadoDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.
Peter J ArtsDepartment of Civil and Environmental Engineering, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-6002-0906
Valerie Le SageDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Evan J AndersonDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
G Marshall LyonDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Eric Charles FittsDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Dalia A GulickDepartment of Civil, Environmental, and Architectural Engineering, University of Kansas, Lawrence, Kansas, USA.
Aneesh K MehtaDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Mikhael F El-ChamiDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Colleen S KraftDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0003-1757-8477
Krista R WiggintonDepartment of Civil and Environmental Engineering, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-6665-5112
Anice C LowenDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-9829-112X
Linsey C MarrDepartment of Civil and Environmental Engineering, Virginia Tech, Blacksburg, Virginia, USA.
Nadine G RouphaelHope Clinic, Emory University, Decatur, Georgia, USA.ORCID 0000-0002-2512-7919
Seema S LakdawalaDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-7679-2150

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00017 · NIAID · EMORY UNIVERSITY · PI LOWEN, ANICE · 2021 to 2025
$27.3M
Emory University internal fundsFlu LabNIAID NIH HHS 75N93021C00017
6 · The paper itself

Abstract

Establishing effective mitigation strategies to reduce the spread of influenza virus requires an improved understanding of the mechanisms of transmission. We evaluated the use of a controlled human infection model using an H3N2 seasonal influenza virus to study critical aspects of transmission, including symptom progression and the dynamics of virus shedding. Eight volunteers were challenged with influenza A/Perth/16/2009 (H3N2) virus between July and September 2022 at Emory University Hospital. Viral shedding in the nasopharynx, saliva, stool, urine, and respiratory aerosols was monitored over the quarantine period, and symptoms were tracked until day 15. In addition, environmental swabs were collected from participant rooms to examine fomite contamination, and participant sera were collected to assess seroconversion by hemagglutination inhibition or microneutralization assays. Among the eight participants, influenza virus infection was confirmed in six (75%). Infectious virus or viral RNA was found in multiple physiological compartments, fecal samples, aerosol particles, and on surfaces in the immediate environment. Illness was moderate, with upper respiratory symptoms dominating. In participants with the highest viral loads, antibody titers rose by day 15 post-inoculation, while in participants with low or undetectable viral loads, there was little or no increase in functional antibody titers. These data demonstrate the safety and utility of the human infection model to study features critical to influenza virus transmission dynamics in a controlled manner and will inform the design of future challenge studies focused on modeling and limiting transmission.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT05332899. IMPORTANCE: We use a controlled human infection model to assess respiratory and aerosol shedding kinetics to expand our knowledge of influenza infection dynamics and help inform future studies aimed at understanding human-to-human transmission.

Indexed as

AerosolsInfluenza A Virus, H3N2 SubtypeInfluenza, HumanViral LoadVirus SheddingAdultAntibodies, ViralFecesFemaleHumansKineticsMaleMiddle AgedNasopharynxRNA, ViralSalivaAerosolsAntibodies, ViralRNA, Viralaerosolsantibody responsecontrolled human infection modelinfluenzainfluenza-like illnessvirus shedding

Identifiers

PMID39589151
PMCPMC11657674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.